From: Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias
Characteristic | No statin (n = 212; 50%) | statin (n = 212; 50%) | p value | ||
---|---|---|---|---|---|
Left ventricular ejection function, n (%) | |||||
LVEF ≥55% | 63 | (30) | 60 | (28) | 0.352 |
LVEF 54–35% | 63 | (30) | 62 | (29) | |
LVEF < 35% | 86 | (41) | 90 | (43) | |
Cardiac therapies at index, n (%) | |||||
Cardiopulmonary resuscitation | 61 | (29) | 51 | (24) | 0.271 |
In hospital | 26 | (12) | 21 | (10) | 0.439 |
Out of hospital | 35 | (17) | 30 | (14) | 0.500 |
External defibrillation | 59 | (28) | 51 | (24) | 0.375 |
External cardioversion | 13 | (6) | 9 | (4) | 0.381 |
Systemic thrombolysis | 7 | (3) | 5 | (2) | 0.558 |
Targeted temperature management (TTM) | 5 | (2) | 8 | (4) | 0.398 |
Coronary artery disease, n (%) | |||||
Coronary angiography, overall | 131 | (62) | 140 | (66) | 0.363 |
Coronary artery disease, n (%) | |||||
No evidence of CAD | 47 | (36) | 41 | (29) | 0.425 |
1-vessel | 24 | (18) | 33 | (24) | |
2-vessel | 27 | (21) | 24 | (17) | |
3-vessel | 33 | (25) | 42 | (30) | |
CTO | 32 | (24) | 27 | (19) | 0.305 |
Presence of CABG | 15 | (12) | 30 | (21) | 0.027 |
Intracoronary thrombus | 2 | (2) | 6 | (4) | 0.180 |
CPR during coronary angiography | 4 | (3) | 3 | (2) | 0.715 |
PCI, n (%) | 28 | (21) | 43 | (31) | 0.081 |
Target lesions | |||||
RCA | 11 | (5) | 16 | (8) | 0.320 |
LMT | 1 | (0.5) | 0 | (0) | 1.000 |
LAD | 15 | (7) | 18 | (9) | 0.587 |
RIM | 0 | (0) | 0 | (0) | – |
LCX | 6 | (3) | 12 | (6) | 0.148 |
Bypass graft | 0 | (0) | 3 | (1) | 0.248 |
Electrical therapies at index, n (%) | |||||
Electrophysiological examination | 72 | (34) | 88 | (42) | 0.109 |
Catheter ablation | 18 | (9) | 19 | (9) | 0.863 |
Newly implanted devices at index, n (%) | |||||
ICD | 54 | (26) | 54 | (26) | 1.000 |
CRT-D | 3 | (1) | 8 | (4) | 0.127 |
CRT-P | 1 | (0.5) | 0 | (0) | 1.000 |
Pacemaker | 4 | (2) | 2 | (0.9) | 0.685 |
Cardiac contractility modulation (CCM) | 0 | (0) | 0 | (0) | – |
Subcutaneous ICD | 0 | (0) | 1 | (0.9) | 1.000 |
Overall implanted devices | 124 | (59) | 121 | (57) | 0.768 |
Medication at discharge, n (%) | |||||
Beta-blocker | 162 | (76) | 187 | (88) | 0.001 |
ACE-inhibitor | 115 | (54) | 153 | (72) | 0.001 |
AT1-Antagonist | 21 | (10) | 29 | (14) | 0.249 |
Aldosteron-antagonist | 22 | (10) | 33 | (16) | 0.112 |
Aspirin only | 58 | (27) | 78 | (37) | 0.037 |
Thienopyridine only | 4 | (2) | 10 | (5) | 0.103 |
Dual antiplatelet therapy | 25 | (12) | 52 | (25) | 0.001 |
Vitamin k antagonist | 54 | (26) | 48 | (23) | 0.495 |
NOAC | 7 | (3) | 2 | (0.9) | 0.175 |
Amiodarone | 54 | (26) | 38 | (18) | 0.059 |
Digitalis | 33 | (16) | 38 | (18) | 0.515 |
Hospitalization time, days, (median (IQR)) | |||||
Total hospitalization time | 16 (8–27) | 14 (8–26) | 0.009 | ||
ICU time | 3 (0–11) | 2 (0–7) | 0.004 | ||
Follow-up time, days, (mean; median (range)) | 1849; 1806 (25–5095) | 1853; 1675 (18–5091) | 0.013 | ||
All cause-mortality at 3 years, n (%) | 70 | (33) | 33 | (16) | 0.001 |